We are developing a next generation of FUROSCIX® utilizing West Pharmaceutical Services, Inc.’s (West) SmartDose® drug delivery platform, leveraging the success of the SmartDose Generation I (Gen. I) device. The FUROSCIX On-body Infusor will incorporate the SmartDose platform, which offers patients a wearable, subcutaneous injector with an integrated drug delivery system that adheres to the body, enabling hands-free outpatient administration of FUROSCIX. Features of the SmartDose system will allow patients to precisely and reliably self-administer FUROSCIX in accordance with their prescribed treatment. West developed this wearable technology with extensive human factors testing and analysis to understand the interaction between the patient and the delivery system.

Features of the SmartDose system will allow patients to precisely and reliably self-administer FUROSCIX in accordance with their prescribed treatment

 

PATIENT-CENTRIC FEATURES

The SmartDose Gen. I device is a fully integrated drug delivery system designed with a variety of patient-centric features, including pre-filled, disposable cartridges for easy user-loading, a pre-programmed drug delivery profile, and visual, tactile and audible feedback to boost user confidence. 

Incorporates West’s SmartDose platform technology—This platform technology has been previously approved by FDA and EMEA as part of a combination product

The SmartDose Gen. I device is a component of another combination therapy that has received approval from the U.S. Food and Drug Administration, and is designed for delivery volumes of 3.5 mL. The FUROSCIX On-body Infusor will use second-generation (Gen. II) SmartDose platform technology that can accommodate a 10 mL delivery volume.  The Gen. II SmartDose device is shown in the image below.

 
preliminary FEASIBILITY STUDIES CONFIRM SUCCESSFUL FUROSCIX DELIVERY AND DRUG STABILITY, compatibility and overall performance within furoscix delivery specifications

We recently completed preliminary feasibility studies on the SmartDose drug delivery system, confirming its ability to successfully deliver FUROSCIX.  These feasibility tests included drug stability in the pre-filled cartridge, drug compatibility, and overall performance within FUROSCIX delivery specifications.  The FUROSCIX On-body Infusor will incorporate the Gen. II SmartDose device, which can accommodate the larger delivery volumes needed for appropriate FUROSCIX dosing. 

SmartDose® and the external product configuration of West’s SmartDose® drug delivery platform are the intellectual property of West Pharmaceutical Services, Inc. or one of its subsidiaries, in the United States and other countries.

The SmartDose Gen. I device is a fully integrated drug delivery system

 

Patient-centric features include:

  • pre-filled, disposable cartridges for easy user-loading
  • a pre-programmed drug delivery profile
  • visual, tactile and audible feedback to boost user confidence
  • hands-free administration
  • fully-integrated delivery system